Algert Global LLC Purchases Shares of 10,900 Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Algert Global LLC purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 10,900 shares of the biopharmaceutical company's stock, valued at approximately $521,000.

A number of other institutional investors have also recently made changes to their positions in HALO. Heck Capital Advisors LLC purchased a new stake in Halozyme Therapeutics during the 4th quarter worth about $29,000. CBIZ Investment Advisory Services LLC bought a new position in Halozyme Therapeutics during the 4th quarter worth approximately $29,000. Smartleaf Asset Management LLC grew its position in Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 197 shares during the last quarter. Venturi Wealth Management LLC bought a new position in Halozyme Therapeutics during the 4th quarter worth approximately $69,000. Finally, Parkside Financial Bank & Trust grew its position in Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 322 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Insider Transactions at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the sale, the senior vice president now owns 173,756 shares of the company's stock, valued at $10,126,499.68. The trade was a 0.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jeffrey William Henderson sold 4,497 shares of the business's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $60.37, for a total value of $271,483.89. Following the sale, the director now directly owns 28,611 shares of the company's stock, valued at $1,727,246.07. This represents a 13.58% decrease in their position. The disclosure for this sale can be found here. Insiders sold 21,697 shares of company stock worth $1,276,552 over the last quarter. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics Stock Up 4.8%

NASDAQ:HALO traded up $2.36 during trading hours on Friday, reaching $51.31. 1,784,187 shares of the company traded hands, compared to its average volume of 1,591,208. The business's 50-day moving average price is $60.88 and its two-hundred day moving average price is $55.89. The stock has a market capitalization of $6.32 billion, a P/E ratio of 14.95, a P/E/G ratio of 0.42 and a beta of 1.26. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $70.51. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.98 by $0.13. The business had revenue of $264.86 million during the quarter, compared to analysts' expectations of $231.21 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm's quarterly revenue was up 35.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.79 earnings per share. Analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Wall Street Analyst Weigh In

HALO has been the topic of several recent research reports. JPMorgan Chase & Co. raised their price target on Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a research report on Monday, April 21st. Leerink Partners cut Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 target price on the stock. in a research note on Tuesday. Morgan Stanley cut Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and reduced their target price for the company from $73.00 to $62.00 in a research note on Wednesday. Benchmark lowered shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Finally, Leerink Partnrs lowered shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $61.90.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.